Table 2.
Clinical characteristics of the patients (all male) with aortic stenosis.
| Aortic stenosis N = 26 | Normal values | Healthy N = 56 | |
|---|---|---|---|
| Age (years) | 79.4 ± 7.7**** | 60.5 ± 4.3 | |
| BMI (g/m2) | 25.9 ± 3.1 | 18.5–25 | |
| Diabetes mellitus (n) | 8 | 0 | |
| Echocardiography | |||
| Ejection fraction (%) | 45.7 ± 15.9 (n = 17) | >55 | |
| Septum thickness (mm) | 14.5 ± 0.5 (n = 25) | ≤11 | |
| Left ventricular enddiastolic diameter (mm) | 48.9 ± 6 (n = 25) | 42–58 | |
| Aortic valve gradient, mean (mmHg) | 37.4 ± 16.1 | ≤20 | |
| Aortic valve area (cm2) | 0.7 ± 0.18 | >1.5 | |
| Serum | |||
| Musclin (ng/ml) | 2.36 ± 1* | 3.38 ± 2.3 | |
| Creatinine (µmol/l) | 124.5 ± 58 | 59–104 | |
| Clinical classification [% of all patients] | |||
| NYHA I | 15.4 | ||
| NYHA II | 23.1 | ||
| NYHA III | 46.2 | ||
| NYHA IV | 15.4 | ||
| Medication [% of all patients] | |||
| ACE inhibitor | 50 | ||
| Angiotensin receptor antagonist | 19.2 | ||
| β-receptor antagonist | 69.2 | ||
| Diuretic | 69.2 | ||
| Calcium channel antagonist | 38.5 | ||
The mean age and Musclin levels of the healthy individuals (also all male) are shown in addition to normal values.
Data are displayed as mean ± SD or in % of all patients as indicated. BMI denotes body mass index. NYHA indicates New York Heart Association Class. *p = 0.0403 vs. Healthy (determined by two-tailed Mann–Whitney test) and ****p < 0.0001 (determined by two-tailed Student’s t test).